Antimicrobial Viewpoints

About
The Experts
Webinars & Conferences
Antimicrobial Viewpoints
Events
Talk to an expert
JOIN US
My account
- Logout

You are here:Home-Antimicrobial Viewpoints

<br>Getting the most out of antimicrobial surveillance</br><em> – by Mariana Castanheira</em> — Getting the most out of antimicrobial surveillance – by Mariana Castanheira
28 May 2020

<br>COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?</br><em> – by Stephan Harbarth</em> — COVID-19 and antimicrobial resistance: Are there any unknowns that will become known? – by Stephan Harbarth
13 May 2020

<br>COVID-19 and its impact on antimicrobial stewardship</br><em> – by Andrew Seaton</em> — COVID-19 and its impact on antimicrobial stewardship – by Andrew Seaton
30 April 2020

<br>The critical need for alternative approaches to address antibiotic treatment failure</br><em> – by Bob Hancock</em> — The critical need for alternative approaches to address antibiotic treatment failure – by Bob Hancock
16 April 2020

<br>COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever</br><em> – by Manica Balasegaram</em> — COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever – by Manica Balasegaram
2 April 2020

<br>The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation</br><em> – by Ryan Cirz and Kevin Krause</em> — The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation – by Ryan Cirz and Kevin Krause
17 March 2020

<br>Diagnostics to safeguard new and current antibiotics for gonorrhoea</br><em> – by Cassandra Kelly-Cirino and Cecilia Ferreyra</em> — Diagnostics to safeguard new and current antibiotics for gonorrhoea – by Cassandra Kelly-Cirino and Cecilia Ferreyra
22 January 2020

<br>On fireworks and finding ways to address drug-resistance in low- and middle-income countries</br><em> – by Ramanan Laxminarayan</em> — On fireworks and finding ways to address drug-resistance in low- and middle-income countries – by Ramanan Laxminarayan
16 December 2019

<br>Bringing antimicrobial research and development to Africa – the time is now</br><em> – by Greg Basarab and Kelly Chibale</em> — Bringing antimicrobial research and development to Africa – the time is now – by Greg Basarab and Kelly Chibale
3 December 2019

<br>Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why</br><em> – by Tim Jinks</em> — Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why – by Tim Jinks
19 November 2019

<br>A new cephalosporin has been approved</br><em> – by Ursula Theuretzbacher</em> — A new cephalosporin has been approved – by Ursula Theuretzbacher
15 November 2019

<br>Are new antibiotic combinations the solution to the AMR crisis?</br><em> – by Anthony Coates</em> — Are new antibiotic combinations the solution to the AMR crisis? – by Anthony Coates
15 October 2019

1
2
Next »

Share

facebook twitter linkedin reddit Email

REVIVE

REVIVE is a space for everybody with an interest in antimicrobial R&D.

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

Content

Antimicrobial Viewpoints (23)
Conferences (16)
Experts (87)
External webinars (14)
Uncategorized (2)
Webinars (28)

Search site

Search for:

CONNECT

Twitter
LinkedIn
YouTube

GARDP
DNDi

Privacy Policy | Terms of Use | Acceptable Use Policy | Cookie Policy

We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our cookie policy